New drug for chronic angina approved
Ranolazine extended-release tablets (Ranexa, CV Therapeutics) have received FDA approval for the treatment of chronic angina. Ranolazine prolongs the QT interval and should be reserved for patients who have not achieved an adequate response with other antianginal drugs.
New drug for chronic angina approved
Ranolazine extended-release tablets (Ranexa, CV Therapeutics) have received FDA approval for the treatment of chronic angina. Ranolazine prolongs the QT interval and should be reserved for patients who have not achieved an adequate response with other antianginal drugs. The exact mechanism of action is unknown, but the drug has antianginal and anti-ischemic effects that do not depend on reductions in heart rate or blood pressure. According to the company, ranolazine should be used in combination with amlodipine, beta-blockers, or nitrates and its effect on angina rate or exercise tolerance appears to be smaller in women than in men. Ranolazine is available as 500-mg extended-release tablets in bottles of 60 and 500.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
